M42, Rhapsody partner to enhance global health outcomes with Microsoft Azure
DUBAI - Global health leader M42, which is powered by artificial intelligence (AI) and technology, has announced a groundbreaking partnership with Rhapsody, a leading digital health enablement platform, to empower precision medicine initiatives across the UAE and beyond.
This collaboration, powered by Microsoft Azure, aims to redefine healthcare data integration and enhance global health outcomes by delivering cutting-edge solutions for seamless and scalable interoperability. The announcement was made on day one of Arab Health 2025.
By addressing the demand for streamlined and interoperable systems, the new partnership – Rhapsody Envoy Edge by M42 – will leverage the robust infrastructure of Microsoft Azure, enabling broader access and scalability for healthcare organisations worldwide. Its innovative solutions will empower healthcare providers to exchange data effortlessly, enhance patient outcomes and drive operational efficiency. The platform will soon be available on the Microsoft Azure Marketplace.
"Rhapsody Envoy Edge by M42 marks a pivotal moment as we continue to push the boundaries of healthcare innovation. By leveraging the powerful capabilities of Microsoft Azure and combining technological innovation, interoperability expertise and a commitment to patient-centric solutions, the collaboration has the potential to transform how healthcare providers operate. Our combined expertise will drive significant improvements in data exchange and integration, operational efficiency, and ultimately patient outcomes, to create an efficient global healthcare ecosystem," said Khalid Al Amadi, Chief Information Officer, Global Patient Care, M42.
Key highlights of the partnership include: Improving healthcare interoperability: By combining M42's deep expertise in healthcare and life sciences with Rhapsody's best-in-class healthcare integration knowledge and capabilities, this partnership will simplify data exchange, optimise workflows, and enable healthcare systems to focus on patient care.
Powered by Microsoft Azure: The Rhapsody market-leading health data integration platform will be hosted on Microsoft Azure, ensuring enhanced security, reliability and scalability for global healthcare providers.
Available on Microsoft Marketplace: The upcoming launch of Rhapsody Envoy Edge by M42 on Microsoft Azure Marketplace will provide healthcare organisations with easy access to powerful tools that support interoperability, accelerating digital transformation in healthcare worldwide.
'We've built a strong partnership with both M42 and Microsoft, aligned on our shared vision of accelerating the adoption of digital health innovation. Rhapsody Envoy Edge by M42 will make it easier, more efficient, and more effective for healthcare providers to access usable data that is needed to deliver better, more informed patient care,' stated Stuart Heavyside, Chief Revenue Officer of Rhapsody.
Arab Health attendees can visit the M42 booth located in Hall 6 – Gold Zone, Stand B30, to learn more about M42's initiatives, groundbreaking healthcare solutions and collaborative opportunities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
5 hours ago
- Zawya
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
Al Etihad
7 hours ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
Zawya
7 hours ago
- Zawya
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care.' Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region."
